Stay updated on Dolutegravir Rilpivirine Clinical Trial

Sign up to get notified when there's something new on the Dolutegravir Rilpivirine Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dolutegravir Rilpivirine Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page’s footer now displays ClinicalTrials.gov revision v3.8.1 instead of v3.8.0.
    Difference
    0.0%
    Check dated 2026-11-18T01:38:41.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The SWORD-2 clinical trial record is now displayed, including its study design, eligibility criteria, treatment arms, outcomes, locations, publications, and data-sharing details, instead of a 403 error screen.
    Difference
    100%
    Check dated 2026-11-10T21:55:25.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-11-03T22:53:28.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    A general NIH announcement about website terminology appears above the 403 error page, and the displayed site revision changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T22:10:07.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The footer now identifies the site as revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-06T22:21:10.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error instead of the study record, indicating restricted access to the content.
    Difference
    21%
    Check dated 2026-09-22T23:09:22.000Z thumbnail image

Stay in the know with updates to Dolutegravir Rilpivirine Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dolutegravir Rilpivirine Clinical Trial page.